Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avidity Biosciences ( (RNA) ) has provided an announcement.
At a special meeting held virtually on February 26, 2026, Avidity Biosciences stockholders approved the Agreement and Plan of Merger with Novartis AG and the Separation and Distribution Agreement related to the spin-off of assets into Atrium Therapeutics, Inc. Approximately 79.95% of outstanding shares were represented, and the transactions proposal passed with 123,351,048 votes in favor, satisfying the stockholder vote condition for closing the deals.
Stockholders also approved, on a non-binding advisory basis, the merger-related compensation that may be paid to Avidity’s named executive officers in connection with the merger and separation transactions. No other business was conducted at the meeting, and the strong shareholder support clears a key procedural hurdle toward completing the combination with Novartis and the spin-off of Atrium Therapeutics.
The most recent analyst rating on (RNA) stock is a Hold with a $78.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
The score is anchored by strong balance-sheet positioning but weighed down by widening losses and rapidly increasing cash burn. Technicals are supportive (price above major moving averages with positive momentum), and corporate events are favorable given progress toward the Novartis merger, while valuation support is limited due to ongoing losses and no dividend yield provided.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences, Inc. is a biotechnology company that develops RNA-based therapeutics, with its shares widely held by public stockholders. The company operates in the biopharmaceutical sector and is now aligning its corporate structure through a merger with Novartis AG and a spin-off of certain assets into Atrium Therapeutics, Inc., reflecting a strategic repositioning within the life sciences industry.
Average Trading Volume: 2,461,292
Technical Sentiment Signal: Buy
Current Market Cap: $11.29B
Learn more about RNA stock on TipRanks’ Stock Analysis page.